Biotech backer Versant arms itself with record $400M fund, targets a new wave of upstarts
Versant Ventures has once again racked up a record new biotech fund. Fund VI has landed, weighing in at $400 million, well ahead of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
